NextPoint Therapeutics Reveals Initiation of Early-Stage Clinical Study with First Subject Receiving NPX887 for Solid Tumors Containing HHLA2, an Innovative Treatment Aiming to Revitalize Worn-Out T and NK Cells.

APL-1202 (nitroxoline) is a reversible and orally available MetAP2 inhibitor with anti-angiogenic and anti-tumor activities.

argenx has reported that the FDA has granted priority review status for their updated biologics application for VYVGART Hytrulo, aimed at treating chronic inflammatory demyelinating polyneuropathy.

Biotin, also known as vitamin B7 or vitamin H, is one of the B vitamins. It is essential for the metabolism of carbohydrates, fats, and proteins.

Arvinas Reports Initial Human Administration of Experimental PROTAC® Compound ARV-102 for Neurological Disorders Treatment.

On Jan 25, 2024, the 2024 ASCO_GU summarized a phase III trial on first-time bladder cancer patients treated with neoadjuvant intravesical MMC.

Philogen Announces Preliminary Results from Phase III FIBROSARC Study Evaluating Onfekafusp alfa (L19TNF) in Initial Treatment of Advanced or Metastatic Soft Tissue Sarcoma.

Doxycycline hyclate, marketed under the brand name Vibramycin, is a type of antibiotic drug belonging to the tetracycline class.

Innovent Reveals Key Goal Achieved in Phase 3 Study (RESTORE-1) of IBI311 (IGF-1R-Targeting Agent) for Thyroid Eye Condition, Intends to File for Approval with NMPA.

2024 ASCO_GU presented new trial data on infigratinib, an FGFR3 inhibitor, showing promise in clinical use.

Bayer commences a second-stage trial using a novel anti-alpha2 antiplasmin agent in individuals affected by deep venous clots.

BuSpar® (buspirone hydrochloride) is an antianxiety agent that is not chemically or pharmacologically related to the benzodiazepines, barbiturates, or other sedative/anxiolytic drugs.